1.Pharmacovigilance Signal Mining and Analysis of Ustekinumab versus Upadacitinib for Inflammatory Bowel Disease Based on the FAERS Database
Dong XIE ; Yu WANG ; Haojia LIN ; Qiuyue TU ; Hetong ZHANG ; Huizhen LI ; Qinghua YI ; Zhengxiang LI ; Hengjie YUAN ; Xiaocang CAO
Medical Journal of Peking Union Medical College Hospital 2025;16(6):1376-1383
To analyze potential adverse drug events(ADEs) associated with ustekinumab and upadacitinib in the treatment of inflammatory bowel disease(IBD) based on an international authoritative database, thereby providing evidence for clinical medication safety. Data were extracted from the Food and Drug Administration Adverse Event Reporting System(FAERS) database using OpenVigil 2.1. ADE reports were collected for ustekinumab(from Q3 2017 to Q1 2025) and upadacitinib(from Q3 2019 to Q1 2025), where each drug was identified as the primary suspected medication for IBD. Signal detection and statistical analysis were performed using the reporting odds ratio(ROR) and proportional reporting ratio(PRR) methods. A total of 3648 ADE reports for ustekinumab and 3812 for upadacitinib, with each as the primary suspected drug in IBD treatment, were retrieved. Using the ROR-PRR combined detection method, relevant ADE signals were identified. High-frequency ADEs associated with ustekinumab included hypersensitivity reactions, various infections, and brain fog, while those associated with upadacitinib included acne, flatulence, and herpes zoster. System organ class(SOC) analysis of positive signals indicated that both drugs commonly caused ADEs in categories such as Infections and infestations, Gastrointestinal disorders, Nervous system disorders, Skin and subcutaneous tissue disorders, and Respiratory, thoracic, and mediastinal disorders. Among these, Infections and infestations were the most frequent SOC, involving preferred terms such as Escherichia sepsis and Pneumococcal pneumonia. Ustekinumab and upadacitinib exhibit distinct safety profiles in the treatment of IBD. In addition to known ADEs described in the prescribing information, ustekinumab requires close monitoring for hypersensitivity reactions, opportunistic infections, and potential neurological risks. For upadacitinib, attention should be paid to risks of acne, herpes zoster, hypercholesterolemia, and thrombotic events. These findings provide important safety information to support individualized clinical decision-making in IBD management.
2.Association between inflammatory factor levels and clinical prognosis after mechanical thrombectomy in patients with acute ischemic stroke
Rui FENG ; Haojia YU ; Shimeng XIN
Journal of Apoplexy and Nervous Diseases 2024;41(10):933-937
Objective To investigate the effect of the levels of interleukin-2R(IL-2R),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)on the clinical prognosis of patients with acute ischemic stroke(AIS)undergoing me-chanical thrombolysis.Methods A retrospective analysis was performed for 156 AIS patients who underwent mechanical thrombectomy,and related clinical data and laboratory markers of inflammatory factors(IL-2R,IL-6,and TNF-α)were collected.On day 90 after mechanical thrombectomy,the patients were divided into good prognosis group and poor progno-sis group based on modified Rankin Scale(mRS).Univariate and multivariate logistic regression analyses were used to in-vestigate the association between the levels of inflammatory factors and poor prognosis on day 90 after surgery,and the re-ceiver operating characteristic(ROC)curve was plotted to investigate the efficacy of inflammatory factors in predicting poor prognosis.Results The incidence rate of poor prognosis was 67.9%on day 90 after surgery,and after adjustment for confounding factors,the multivariate logistic regression analysis showed that high IL-2R level,high platelet count,bridging therapy,and recanalization with one pull of the bolus were protective factors for the prognosis of AIS patients on day 90 after mechanical thrombolysis[odds ratio(OR)<1,P<0.05],and fasting blood glucose and NIHSS score after thrombectomy were risk factors for poor prognosis on day 90 after mechanical thrombolysis in patients with AIS(OR>1,P<0.05);IL-6 and TNF-α were not independent influencing factors for poor prognosis in patients with AIS on day 90 after mechanical thrombolysis(P>0.05).The ROC curve showed that IL-2R or NIHSS score after thrombectomy used alone or in combination had an area under the ROC curve of 0.801,0.804,and 0.892,respectively,in predicting poor prognosis on day 90 after surgery,and the combination of IL-2R and NIHSS score after thrombectomy had a higher predictive value.Conclusion The high level of IL-2R is independently associated with a good prognosis in AIS patients on day 90 after mechanical thrombolysis,and NIHSS score after thrombectomy combined with IL-2R has better predictive efficacy than NIHSS score after thrombectomy alone.For the time being,no independent effect of IL-6 and TNF-α has been found on the poor prognosis of AIS patients on day 90 after mechanical thrombolysis.
3.Advances in ion channel genes and genetics of epilepsy
Yue LANG ; Xiaofeng WANG ; Jian YIN ; Haojia YU ; Hui ZHANG
Chinese Journal of Neurology 2018;51(8):642-648
Ion channels are crucial in the generation and modulation of excitability in the nervous system.Recent studies have demonstrated that 977 genes are associated with epilepsy,among which more than 60 genes encode ion channels predominantly,mainly including voltage-gated channel genes:sodium channel (SCALA,SCN1B,SCN2A),potassium channel (KCNA2,KCNC1,KCNT1,KCNQ2,KCNQ3),chloride channel (CLCN2),calcium channel (CACNA1H,CACNA1A),and ligand-gated ion channel genes,which include GABA receptor genes (GABRA1,GABRB3,GABRD and GABRG2),neuronal nicotinic receptor genes (CHRNA4,CHRNB2) and other genes (HCN1,LGI1 and PRRT2).This review mainly focuses on the advances in ion channel genes and genetics of epilepsy,in order to assist the diagnoses and treatment in clinic.

Result Analysis
Print
Save
E-mail